Table 1

Baseline characteristics in patients with and without 1-year ischaemic or bleeding events

IE
(n=633)
No-IE
(n=25 186)
P valueMB
(n=784)
No MB
(n=25 035)
P value
Age, years85.0±5.184.4±5.20.00484.8±5.684.4±5.20.06
BMI, kg/m222.0±3.722.4±5.10.0221.6±4.022.4±5.1<0.001
BSA1.42±0.181.43±0.170.021.39±0.181.44±0.17<0.001
Female432 (68%)17 211 (68%)0.96571 (73%)17 072 (68%)0.01
Smoking96 (15%)4005 (16%)0.16115 (15%)3986 (16%)0.34
Diabetes0.57
 Non-insulin-treated155 (25%)5673 (23%)0.25187 (24%)5641 (23%)0.39
 Insulin-treated32 (5%)999 (4%)0.1834 (4%)997 (4%)0.58
 Hypertension526 (83%)19 885 (79%)0.01635 (81%)19 776 (79%)0.18
 Dyslipidaemia328 (52%)12 240 (49%)0.11374 (48%)12 194 (49%)0.58
 PVD151 (24%)2777 (11%)<0.001123 (16%)2785 (11%)<0.001
 Malignancy61 (10%)2318 (9%)0.7169 (9%)2310 (9%)0.68
 CHF421 (67%)15 832 (63%)0.06511 (65%)15 742 (63%)0.19
 CKD (CrCl<60)585 (92%)22 181 (88%)<0.001716 (91%)22 050 (88%)0.01
 Severe CKD237 (37%)7468 (30%)<0.001292 (37%)7413 (30%)<0.001
 Anaemia304 (48%)11 969 (48%)0.80447 (57%)11 826 (47%)<0.001
 Cerebrovascular disease109 (17%)2995 (12%)<0.001103 (13%)3001 (12%)0.33
 COPD202 (32%)7387 (29%)0.16250 (32%)7339 (29%)0.12
 Previous PCI168 (27%)5778 (23%)0.03217 (28%)5729 (23%)0.002
 Previous CABG28 (4%)1137 (5%)0.9140 (5%)1125 (5%)0.42
 Permanent peacemaker36 (6%)1403 (6%)0.9045 (6%)1394 (6%)0.84
 Atrial fibrillation124 (20%)4274 (17%)0.08157 (20%)4241 (17%)0.02
 STS score6.7 [4.6–9.6)6.0 [4.2–8.7)<0.0016.4 [4.5–9.7)6.0 [4.2–8.7)<0.001
Preoperative medications
 Aspirin308 (49%)11 295 (45%)0.06394 (50%)11 209 (45%)0.002
 Thienopyridine3 (0.5%)154 (0.6%)1.007 (0.9%)150 (0.6%)0.34
 Warfarin28 (4%)1399 (6%)0.2260 (8%)1367 (6%)
 DOAC71 (11%)2690 (11%)0.6797 (12%)2664 (11%)
 Triple therapy6 (0.9%)255 (1%)0.8713 (2%)248 (1%)
 Aortic valve area0.6 [0.5–0.8)0.6 [0.5–0.8)0.030.6 [0.5–0.7)0.6 [0.5–0.8)0.11
 Aortic valve gradient46(36-59)46(38-60)0.3346(36-59)46(38-60)0.16
 LVEF64(55-69)64(56-70)0.2464(57-70)64(56-70)0.61
 Moderate or severe AR51 (8%)1817 (7%)0.4248 (6%)1820 (7%)0.22
 Moderate or severe MR49 (8%)2052 (8%)0.7166 (8%)2035 (8%)0.77
 Bicuspid valve17 (3%)529 (2%)0.8614 (2%)652 (3%)0.15
Procedural characteristics
 Prosthesis type
  Balloon expandable405 (64%)18 975 (75%)<0.001569 (73%)18 811 (75%)0.10
  Self-expandable227 (36%)6161 (24%)<0.001209 (27%)6179 (25%)0.21
 Prosthesis size<0.0010.92
  20 mm23 (4%)1290 (5%)43 (5%)1270 (5%)
  23 mm254 (40%)11 154 (44%)337 (43%)11 071 (44%)
  26 mm227 (36%)9168 (36%)287 (37%)9108 (36%)
  29 mm128 (20%)3524 (14%)111 (14%)3541 (14%)
 Transfemoral approach532 (84%)22 375 (89%)0.002650 (83%)22 257 (89%)<0.001
  • AR, aortic regurgitation; BMI, body mass index; BSA, body surface area; CABG, coronary artery bypass grafting; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DOAC, direct oral anticoagulant; IE, ischaemic events; LVEF, left ventricular ejection fraction; MB, major bleeding; MR, mitral regurgitation; PCI, percutaneous coronary intervention; PVD, peripheral vessel disease; STS, Society of Thoracic Surgery.